V3-substanceAdminSubstitution.cs.xml

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="v3-substanceAdminSubstitution"/> 
  <meta> 
    <lastUpdated value="2018-04-01T00:00:00.000+11:00"/> 
  </meta> 
  <text> 
    <status value="generated"/> 
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p> Release Date: 2018-04-01</p> 

      <table class="grid">
 
        <tr> 
          <td> 
            <b> Level</b> 
          </td> 
          <td> 
            <b> Code</b> 
          </td> 
          <td> 
            <b> Display</b> 
          </td> 
          <td> 
            <b> Definition</b> 
          </td> 
        </tr> 
 
        <tr> 
          <td> 1</td> 
          <td> 
            <span style="color: grey">
              <i> (_ActSubstanceAdminSubstitutionCode)</i> 
            </span>  
            <b> 
              <i> Abstract</i> 
            </b> 
          </td> 
          <td> 
            <a name="v3-substanceAdminSubstitution-_ActSubstanceAdminSubstitutionCode"> </a> 
          </td> 
          <td> 
                        
                           Description: Substitution occurred or is permitted with another
               product that may potentially have different ingredients, but having the same biological
               and therapeutic effects.
            <br/>  

                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 2</td> 
          <td>   E
            <a name="v3-substanceAdminSubstitution-E"> </a> 
          </td> 
          <td> equivalent</td> 
          <td> 
                        
                           Description: Substitution occurred or is permitted with another
               bioequivalent and therapeutically equivalent product.
            <br/>  

                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 3</td> 
          <td>     EC
            <a name="v3-substanceAdminSubstitution-EC"> </a> 
          </td> 
          <td> equivalent composition</td> 
          <td> 
                        
                           Description: 
                        
            <br/>  

                        Substitution occurred or is permitted with another product that
               is a:
            <br/>  

                        
                           pharmaceutical alternative containing the same active ingredient
               but is formulated with different salt, ester
                           pharmaceutical equivalent that has the same active ingredient,
               strength, dosage form and route of administration
                        
                        
                           Examples: 
                        
            <br/>  

                        
                           
                              Pharmaceutical alternative: Erythromycin Ethylsuccinate
               for Erythromycin Stearate
                           
                              Pharmaceutical equivalent: Lisonpril for Zestril
                        
                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 4</td> 
          <td>       BC
            <a name="v3-substanceAdminSubstitution-BC"> </a> 
          </td> 
          <td> brand composition</td> 
          <td> 
                        
                           Description: 
                        
            <br/>  

                        Substitution occurred or is permitted between equivalent Brands
               but not Generics
            <br/>  

                        
                           Examples: 
                        
            <br/>  

                        
                           Zestril  for Prinivil
                           Coumadin for Jantoven
                        
                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 4</td> 
          <td>       G
            <a name="v3-substanceAdminSubstitution-G"> </a> 
          </td> 
          <td> generic composition</td> 
          <td> 
                        
                           Description: Substitution occurred or is permitted between
               equivalent Generics but not Brands
            <br/>  

                        
                           Examples: 
                        
            <br/>  

                        
                           Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
                        
                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 3</td> 
          <td>     TE
            <a name="v3-substanceAdminSubstitution-TE"> </a> 
          </td> 
          <td> therapeutic alternative</td> 
          <td> 
                        
                           Description: Substitution occurred or is permitted with another
               product having the same therapeutic objective and safety profile.
            <br/>  

                        
                           Examples: 
                        
            <br/>  

                        
                           ranitidine for Tagamet
                        
                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 4</td> 
          <td>       TB
            <a name="v3-substanceAdminSubstitution-TB"> </a> 
          </td> 
          <td> therapeutic brand</td> 
          <td> 
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Brands but not Generics
            <br/>  
&gt;
                           Examples: 
                        
            <br/>  

                        
                           Zantac for Tagamet
                        
                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 4</td> 
          <td>       TG
            <a name="v3-substanceAdminSubstitution-TG"> </a> 
          </td> 
          <td> therapeutic generic</td> 
          <td> 
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Generics but not Brands
            <br/>  
&gt;
                           Examples: 
                        
            <br/>  

                        
                           Ranitidine  for cimetidine
                        
                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 2</td> 
          <td>   F
            <a name="v3-substanceAdminSubstitution-F"> </a> 
          </td> 
          <td> formulary</td> 
          <td> 
                        
                           Description: This substitution was performed or is permitted
               based on formulary guidelines. 
            <br/>  

                     
          </td> 
        </tr> 
 
        <tr> 
          <td> 2</td> 
          <td>   N
            <a name="v3-substanceAdminSubstitution-N"> </a> 
          </td> 
          <td> none</td> 
          <td> 
                        No substitution occurred or is permitted.
            <br/>  

                     
          </td> 
        </tr> 

      </table> 

    </div> 
  </text> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-ballot-status">
    <valueString value="External"/> 
  </extension> 
  <extension url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm">
    <valueInteger value="0"/> 
  </extension> 
  <url value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/> 
  <identifier> 
    <system value="urn:ietf:rfc:3986"/> 
    <value value="urn:oid:2.16.840.1.113883.5.1070"/> 
  </identifier> 
  <version value="2018-04-01"/> 
  <name value="v3 Code System substanceAdminSubstitution"/> 
  <status value="active"/> 
  <experimental value="false"/> 
  <date value="2018-04-01T00:00:00+11:00"/> 
  <publisher value="HL7, Inc"/> 
  <contact> 
    <telecom> 
      <system value="url"/> 
      <value value="http://hl7.org"/> 
    </telecom> 
  </contact> 
  <description value=" Identifies what sort of change is permitted or has occurred between the therapy that
     was ordered and the therapy that was/will be provided."/> 
  <caseSensitive value="true"/> 
  <valueSet value="http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution"/> 
  <hierarchyMeaning value="is-a"/> 
  <content value="complete"/> 
  <property> 
    <code value="notSelectable"/> 
    <uri value="http://hl7.org/fhir/concept-properties#notSelectable"/> 
    <description value="Indicates that the code is abstract - only intended to be used as a selector for other
       concepts"/> 
    <type value="boolean"/> 
  </property> 
  <concept> 
    <code value="_ActSubstanceAdminSubstitutionCode"/> 
    <display value="ActSubstanceAdminSubstitutionCode"/> 
    <definition value="Description: Substitution occurred or is permitted with another product that may potentially
       have different ingredients, but having the same biological and therapeutic effects."/> 
    <property> 
      <code value="notSelectable"/> 
      <valueBoolean value="true"/> 
    </property> 
    <concept> 
      <code value="E"/> 
      <display value="equivalent"/> 
      <definition value="Description: Substitution occurred or is permitted with another bioequivalent and therapeutically
         equivalent product."/> 
      <concept> 
        <code value="EC"/> 
        <display value="equivalent composition"/> 
        <definition value="Description: 
                        

                        Substitution occurred or is permitted with another product that
           is a:

                        
                           pharmaceutical alternative containing the same active ingredient
           but is formulated with different salt, ester
                           pharmaceutical equivalent that has the same active ingredient,
           strength, dosage form and route of administration
                        
                        
                           Examples: 
                        

                        
                           
                              Pharmaceutical alternative: Erythromycin Ethylsuccinate
           for Erythromycin Stearate
                           
                              Pharmaceutical equivalent: Lisonpril for Zestril"/> 
        <concept> 
          <code value="BC"/> 
          <display value="brand composition"/> 
          <definition value="Description: 
                        

                        Substitution occurred or is permitted between equivalent Brands
             but not Generics

                        
                           Examples: 
                        

                        
                           Zestril  for Prinivil
                           Coumadin for Jantoven"/> 
        </concept> 
        <concept> 
          <code value="G"/> 
          <display value="generic composition"/> 
          <definition value="Description: Substitution occurred or is permitted between equivalent Generics but not
             Brands

                        
                           Examples: 
                        

                        
                           Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)"/> 
        </concept> 
      </concept> 
      <concept> 
        <code value="TE"/> 
        <display value="therapeutic alternative"/> 
        <definition value="Description: Substitution occurred or is permitted with another product having the same
           therapeutic objective and safety profile.

                        
                           Examples: 
                        

                        
                           ranitidine for Tagamet"/> 
        <concept> 
          <code value="TB"/> 
          <display value="therapeutic brand"/> 
          <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
             Brands but not Generics
&gt;
                           Examples: 
                        

                        
                           Zantac for Tagamet"/> 
        </concept> 
        <concept> 
          <code value="TG"/> 
          <display value="therapeutic generic"/> 
          <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
             Generics but not Brands
&gt;
                           Examples: 
                        

                        
                           Ranitidine  for cimetidine"/> 
        </concept> 
      </concept> 
    </concept> 
    <concept> 
      <code value="F"/> 
      <display value="formulary"/> 
      <definition value="Description: This substitution was performed or is permitted based on formulary guidelines."/> 
    </concept> 
    <concept> 
      <code value="N"/> 
      <display value="none"/> 
      <definition value="No substitution occurred or is permitted."/> 
    </concept> 
  </concept> 
</CodeSystem>